Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin Dose-Response for Lower Limb Spasticity in Pediatric CP
NCT01893411Phase 3Completed
- Sponsor
- Merz
- Start
- Jun 2013
- Primary completion
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
A Phase 3 trial of incobotulinumtoxinA in spasticity, sponsored by Merz. Started Jun 2013; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT01893411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01893411.